InvestorsHub Logo
icon url

scrapper77

09/27/14 10:48 AM

#4489 RE: wilma6311 #4486

Wilma, gonna be hilarious that people lose moey? says a lot about the person posting!
icon url

Chachagirl

09/27/14 10:48 AM

#4490 RE: wilma6311 #4486

He did in fact do a reverse merger. The public filings with the SEC are crystal clear.

In a prior post you stated you do not own shares. Why are you here?
icon url

HMB2010

09/27/14 1:17 PM

#4498 RE: wilma6311 #4486

WHO IS DSS?? PLEASE POST LINK so we can all look at what you are quoting from and decide for ourselves if your DD is applicable to the situation with KEYO
Thank you
icon url

TrueTrades

09/27/14 1:43 PM

#4500 RE: wilma6311 #4486

PSS's IPO with APP is certainly legendary! A brief synopsis of what transpired afterward:
"American Pharmaceutical Partners, Inc. (APP) is a publicly traded specialty pharmaceutical company based in Schaumburg, Illinois. Often during its brief history, the company has been at the center of controversy and at times skirted scandal. Its chairman, Dr. Patrick Soon-Shiong, owns about 70 percent of APP through his control of another company, American BioScience. Over the years, the results of much of his research have been questioned, and he also has been involved in a number of disputes with business partners, including an estranged brother who fired Soon-Shiong and sued him in the 1990s. Wall Street short-sellers have been gunning for APP since its 2001 initial public offering (IPO), convinced that Soon-Shiong's high-wire act was due for a fall. In particular, his doubters question claims about the effectiveness of a new cancer drug for which APP has been seeking Food and Drug Administration (FDA) approval, a case that has prompted the Securities and Exchange Commission to review and consider launching a formal investigation. Despite the notoriety surrounding its attempt to launch its first proprietary blockbuster drug, APP has developed a very profitable business in injectable pharmaceutical products, offering more than 150 generic injectables in more than 300 dosages, focusing primarily on the oncology, anti-infective, and critical care markets."
SOURCE:
http://www.answers.com/topic/american-pharmaceutical-partners-inc

Do you think he's going to let that happen again?
§KEYO